Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.
3 reports, 2 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.Also in this story
- Adagene Inc. presented data regarding its ADG126 therapy at a CSCO meeting, with mentions of locations including Jinan and Suzhou.
- Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.
The entities involved
Coverage
Newest first; wire copies grouped- Business WireZai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong SHANGHAI & CAMBRIDGE, Mass., September 02, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ:
- Investing.comGenmab raises full-year outlook, shares rise Investing.com -- Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key partner drugs. T